Precipio Inc
Precipio Inc has a market capitalization of $51.05 million and a price-to-book ratio of 4.0, indicating a premium valuation relative to its book value. The company's liquidity position is weak, with a current ratio of 0.78, suggesting that it may struggle to meet short-term obligations with its current assets. Additionally, the company reported negative operating and free cash flows of $667,000 and $1.76 million, respectively, indicating a lack of cash generation from operations. The company's profitability is underperforming, with a return on equity of -16.28% and a return on assets of -12.51%, both significantly below the industry median for Advanced Medical Equipment & Technology. The negative net income of $2.08 million and operating income of $2.07 million further highlight the company's financial challenges. These metrics suggest that the company is not generating sufficient returns to justify its capital structure or to compete effectively in its industry. Precipio Inc's revenue is concentrated in the United States, with no disclosed international operations. The company's business is primarily driven by its diagnostic and genomic testing services, which are offered to healthcare providers. There is no indication of significant diversification across product lines or geographic regions. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The lack of positive operating cash flow and the negative net income suggest that the company is not currently expanding its operations or increasing its market share. The company's financial performance indicates a need for strategic adjustments to improve profitability and cash flow generation. The risk assessment for Precipio Inc indicates a low level of liquidity and dilution risk. However, the company's negative operating and free cash flows, along with its low current ratio, suggest that it may face liquidity challenges in the near term. The company has not disclosed any immediate filing-based liquidity or dilution flags, but its financial performance indicates a need for careful monitoring of its capital structure and cash flow management. Recent events and filings for Precipio Inc do not indicate any significant changes in the company's financial or operational status. The company's latest financial report shows continued losses and negative cash flows, which may impact its ability to sustain operations without additional financing. There are no disclosed recent events that would significantly alter the company's risk profile or financial outlook.
Business. Precipio Inc provides diagnostic and genomic testing services to healthcare providers, primarily in the United States.
Classification. Precipio Inc is classified in the Healthcare sector under the Advanced Medical Equipment & Technology industry with a confidence level of 0.92.
- Precipio Inc is trading at a price-to-book ratio of 4.0, indicating a premium valuation relative to its book value.
- The company's return on equity of -16.28% and return on assets of -12.51% are significantly below the industry median for Advanced Medical Equipment & Technology.
- Precipio Inc has a current ratio of 0.78, suggesting potential liquidity challenges in meeting short-term obligations.
- The company reported negative operating and free cash flows of $667,000 and $1.76 million, respectively, indicating a lack of cash generation from operations.
- --
- # RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.